Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?

Challenges have been recognized in healthcare of patients with Alzheimer’s disease (AD) in the COVID-19 pandemic, given a high infection and mortality rate of COVID-19 in these patients. This situation urges the identification of underlying risks and preferably biomarkers for evidence-based, more ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Nian, Schiller, Martin R., Li, Jingwen, Chen, Xiaowu, Lin, Zhicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197596/
https://www.ncbi.nlm.nih.gov/pubmed/34118974
http://dx.doi.org/10.1186/s13195-021-00858-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197596/
https://www.ncbi.nlm.nih.gov/pubmed/34118974
http://dx.doi.org/10.1186/s13195-021-00858-9

Ejemplares similares